Quantum-Si to Present at BioConnect Conference Amidst Proteomics Investment Scrutiny
Event summary
- Quantum-Si (QSI) will participate in the H.C. Wainwright BioConnect Investor Conference on May 19, 2026.
- CEO Jeff Hawkins and CFO Jeff Keyes will conduct one-on-one meetings with investors.
- Hawkins will deliver a fireside chat at 4:00 PM ET on May 19, 2026, with a live webcast available.
- The conference is located at 151 West 42nd Street, New York, NY.
The big picture
Quantum-Si’s participation in the BioConnect conference highlights the ongoing investor interest in proteomics, a field experiencing increased attention due to its potential to revolutionize drug discovery and diagnostics. However, proteomics companies face significant challenges in achieving widespread adoption and demonstrating a clear return on investment, particularly as capital markets tighten. The conference provides a key opportunity for Quantum-Si to articulate its value proposition and address investor concerns.
What we're watching
- Investor Sentiment
- The conference appearance will be a key test of investor confidence given the capital-intensive nature of proteomics platform development and the current macroeconomic climate.
- Technology Adoption
- The success of Quantum-Si’s platform hinges on its ability to displace established, multistep workflows; the fireside chat should reveal progress on adoption rates within research labs.
- Competitive Landscape
- Increased scrutiny of proteomics companies may intensify competition, and Quantum-Si’s ability to demonstrate a clear technological advantage will be crucial for maintaining market share.
Related topics